Thyme Care Secures Over $125M Series E Funding at a Valuation Exceeding $2B
Thyme Care, an oncology company focused on improving cancer care through cost-effective solutions, has raised over $125 million in its latest Series E funding round. The investment was led by Morgan Health and included participation from strategic investors such as Humana and CVS Health Ventures, among others. This financing values the company at more than $2 billion and will support Thyme Care's growth while establishing a new parent entity called Thyme Companies. Thyme Companies aims to build a broader portfolio of businesses addressing various aspects of cancer care, including biosimilar adoption and clinical trial enrollment challenges. The initiative is backed by strong financial performance from Thyme Care, which services over 10.5 million people nationwide and manages more than $7 billion in oncology spend while delivering cost reductions for stakeholders. The new entity will be led by co-founder Robin Shah as executive chairman alongside CEO Brad Diephuis, M.D., with plans to launch its first business later this year.
Topics: funding_round healthcare investment oncology